Effects of Pazopanib on Hereditary Hemorrhagic Telangiectasia Related Epistaxis and Anemia (Paz)

Key facts

Sponsor

Cure HHT

Principal Investigator

James Gossage, MD

Augusta University

Intervention

Pazopanib(drug)

Enrollment

70 enrolled

Eligibility

18-85 years · All sexes

Timeline

2023 – 2026

Study locations (11)

• University of California - Los Angeles, Los Angeles, California, United States
• University of Colorado, Denver, Colorado, United States
• Augusta University, Augusta, Georgia, United States
• John Hopkins University, Baltimore, Maryland, United States
• Massachusetts General Hospital, Boston, Massachusetts, United States
• Mayo Clinic, Rochester, Minnesota, United States
• Washington University, St Louis, Missouri, United States
• University of North Carolina, Chapel Hill, North Carolina, United States
• Cleveland Clinic, Cleveland, Ohio, United States
• University of Texas - Southwestern, Dallas, Texas, United States
• University of Utah Medical Center, Salt Lake City, Utah, United States

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Other trials for Hereditary hemorrhagic telangiectasia

Additional recruiting or active studies for the same condition.

• RECRUITINGPHASE1NCT07255846
  A Trial of TER-1754 in Patients With Hereditary Hemorrhagic Telangiectasia
  Terremoto Biosciences Inc.
• ENROLLING BY INVITATIONNCT07445347
  Efficacy and Tolerance of Treatment With Bevacizumab for Severe Liver Involvement With High Cardiac Output in Hereditary Hemorrhagic Telangiectasia Within the French Hereditary Hemorrhagic Telangiectasia Network
  Poitiers University Hospital
• RECRUITINGPHASE1, PHASE2NCT06659640
  A Study to Evaluate ALN-6400 in Healthy Volunteers and Patients With Hereditary Hemorrhagic Telangiectasia (HHT)
  Alnylam Pharmaceuticals
• ACTIVE NOT RECRUITINGNCT07018401
  Pomalidomide for the Treatment of Bleeding in Hereditary Hemorrhagic Telangiectasia Longitudinal Assessment Study
  Massachusetts General Hospital
• ENROLLING BY INVITATIONNCT06261333
  Quality of Life in Patients With Hemorrhagic Telangiectasia
  University Hospital, Essen
• RECRUITINGNANCT05641142
  Prospective Study of Antiplatelet and Anticoagulation Therapy in Hereditary Haemorrhagic Telangiectasia
  University Hospital, Clermont-Ferrand
• ACTIVE NOT RECRUITINGPHASE1, PHASE2NCT05406362
  Assess Safety and Efficacy of VAD044 in HHT Patients
  Vaderis Therapeutics AG
• RECRUITINGPHASE2NCT04976036
  Efficacy of Nintedanib for Treatment of Epistaxis in Hereditary Hemorrhagic Telangiectasia (HHT) Patients
  Dr. Romain Lazor

See all trials for Hereditary hemorrhagic telangiectasia →